A total of 83 patents worldwide have been issued relating to ISA247’s structure, composition, formulation and methods of synthesis. ISA247 is currently being investigated in a Phase IIb North American trial for the prevention of kidney graft rejection subsequent to transplantation and a Phase III European/Canadian psoriasis trial.
Robert Foster, Isotechnika’s chairman and CEO, said: “In accordance with our overall strategic plan, we continue to secure patent protection worldwide in anticipation of acquiring market approval for ISA247. This indicates that ISA247 will have exclusivity for at least another 15 years. Additional claims for ISA247 will be pursued to ensure that intellectual property is secured in all of the major markets worldwide.”